FDx Advisors’s GSK GSK Stock Holding History

FDx Advisors’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-4,568	Closed	-$214K	–	118
2025 Q3	$214K	Buy	+4,568	New	+$178K	0.06%	171
2024 Q1	–	Sell	-34,131	Closed	-$1.26M	–	474
2023 Q4	$1.26M	Buy	34,131 +14,816	+77%	+$532K	0.1%	206
2023 Q3	$700K	Buy	19,315 +2,316	+14%	+$82.2K	0.06%	283
2023 Q2	$606K	Buy	+16,999	New	+$610K	0.03%	401
2022 Q4	–	Sell	-15,864	Closed	-$467K	–	758
2022 Q3	$467K	Buy	15,864 +1,550	+11%	+$58.7K	0.02%	421
2022 Q2	$779K	Buy	14,314 +2,150	+18%	+$119K	0.03%	368
2022 Q1	$662K	Buy	+12,164	New	+$661K	0.02%	424
2021 Q4	–	Sell	-7,545	Closed	-$360K	–	860
2021 Q3	$360K	Hold	7,545	–	–	0.01%	599
2021 Q2	$376K	Sell	7,545 -4,669	-38%	-$224K	0.01%	593
2021 Q1	$545K	Buy	12,214 +2,807	+30%	+$127K	0.02%	447
2020 Q4	$433K	Sell	9,407 -10,935	-54%	-$502K	0.02%	481
2020 Q3	$957K	Sell	20,342 -13,384	-40%	-$671K	0.04%	242
2020 Q2	$1.72M	Buy	33,726 +6,436	+24%	+$330K	0.09%	163
2020 Q1	$1.29M	Sell	27,290 -1,703	-6%	-$90.8K	0.08%	167
2019 Q4	$1.7M	Sell	28,993 -968	-3%	-$53.8K	0.09%	166
2019 Q3	$1.6M	Sell	29,961 -25,239	-46%	-$1.3M	0.11%	160
2019 Q2	$2.76M	Sell	55,200 -3,880	-7%	-$195K	0.11%	153
2019 Q1	$3.09M	Buy	59,080 +24,000	+68%	+$1.2M	0.13%	131
2018 Q4	$1.68M	Sell	35,080 -23,583	-40%	-$1.16M	0.14%	118
2018 Q3	$2.95M	Sell	58,663 -3,717	-6%	-$189K	0.11%	144
2018 Q2	$3.14M	Sell	62,380 -11,319	-15%	-$570K	0.11%	145
2018 Q1	$3.6M	Sell	73,699 -24,169	-25%	-$1.13M	0.11%	153
2017 Q4	$4.34M	Sell	97,868 -4,850	-5%	-$224K	0.12%	144
2017 Q3	$5.21M	Buy	102,718 +23,367	+29%	+$1.19M	0.14%	116
2017 Q2	$4.28M	Sell	79,351 -2,122	-3%	-$113K	0.13%	139
2017 Q1	$4.29M	Sell	81,473 -24,126	-23%	-$1.22M	0.13%	141
2016 Q4	$5.08M	Buy	105,599 +11,416	+12%	+$564K	0.15%	127
2016 Q3	$5.08M	Sell	94,183 -4,726	-5%	-$259K	0.21%	89
2016 Q2	$5.36M	Buy	98,909 +20,645	+26%	+$1.09M	0.24%	78
2016 Q1	$3.97M	Buy	78,264 +16,174	+26%	+$806K	0.18%	100
2015 Q4	$3.13M	Buy	62,090 +52,392	+540%	+$2.67M	0.14%	123
2015 Q3	$466K	Sell	9,698 -8,074	-45%	-$420K	0.04%	471
2015 Q2	$925K	Sell	17,772 -21,268	-54%	-$1.2M	0.05%	361
2015 Q1	$2.25M	Buy	39,040 +25,033	+179%	+$1.44M	0.05%	304
2014 Q4	$748K	Buy	14,007 +6,111	+77%	+$342K	0.05%	404
2014 Q3	$454K	Buy	7,896 +602	+8%	+$36.9K	0.03%	627
2014 Q2	$488K	Buy	7,294 +2,304	+46%	+$156K	0.03%	593
2014 Q1	$333K	Buy	+4,990	New	+$337K	0.03%	573

Other funds holding GSK

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

JEST

JTC Employer Solutions Trustee St Helier, Jersey $1.25B AUM 41.83% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

FDx Advisors's GSK Position: Q4 2025 in Review

FDx Advisors sold out of GSK (GSK) in Q4 2025, closing a stake of 4,568 shares — an estimated $214K sold.

FDx Advisors first reported a position in GSK in Q1 2014 and held it in 38 quarters. The position peaked at $5.36M in Q2 2016. 996 funds tracked by Wall St. Rank hold GSK as of Q4 2025.

FDx Advisors reported no remaining GSK position as of Q4 2025 after selling out during the quarter.
FDx Advisors sold 4,568 GSK shares in Q4 2025, an estimated $214K.
FDx Advisors first reported a position in GSK in Q1 2014 and held it in 38 quarters.
FDx Advisors's GSK position peaked at $5.36M in Q2 2016.
996 funds tracked by Wall St. Rank held GSK as of Q4 2025.

Based on FDx Advisors's 13F filing for Q4 2025, filed 10 Feb 2026.